Print Page  Close Window

SEC Filings

OREXIGEN THERAPEUTICS, INC. filed this Form S-1/A on 04/09/2007
Entire Document

(3)   Performance of any part of this Agreement by a party is prevented or delayed by reason of Force Majeure and cannot be overcome by reasonable diligence to the satisfaction of either party;
(4)   The other party ceases, discontinues or indefinitely suspends its business activities related to the services to be provided under this Agreement, or the other party voluntarily or involuntarily files for bankruptcy; or
(5)   The party has given ninety (90) days written notice to the other party.
The party requesting termination will provide the other party with written notice specifying both the reason and the effective date of termination. Upon the giving of such notice of termination by either party, the UNIVERSITY will use its reasonable best efforts to limit or terminate any outstanding commitments.
Upon termination, UNIVERSITY shall deliver to SPONSOR in the state they exist as of the date of termination of all work product, and Confidential Information belonging to SPONSOR. SPONSOR shall within thirty (30) days after termination pay UNIVERSITY all payments due as of the effective date of termination.
The provisions of Articles V, VII, X, XI, XII, and XIV shall survive termination of this Agreement.
All notices or communications given hereunder shall be in writing and shall be delivered by hand, or by overnight courier, by facsimile with confirmation by mail, with all delivery charges prepaid and addressed to the parties as follows:
  Orexigen Therapeutics, Inc
  12481 High Bluff Drive
  San Diego, CA 92130
  Phone: (858) 480-2420
  Fax: (848) 480-2401
  Director, Technology & Research Collaborations
  Oregon Health & Science University, AD120
  2525 SW First Avenue, Suite 120
  Portland, OR 97201-4753
  Telephone: (503) 494-8200
  Fax: (503) 494-4729
  with copy to
  Michael Cowley, Ph.D.